TY - JOUR
T1 - Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome
AU - Shnaper, Sophie
AU - Desbaillets, Isabelle
AU - Brown, David A.
AU - Murat, Anastasia
AU - Migliavacca, Eugenia
AU - Schluep, Myriam
AU - Ostermann, Sandrine
AU - Hamou, Marie France
AU - Stupp, Roger
AU - Breit, Samuel N.
AU - De Tribolet, Nicolas
AU - Hegi, Monika E.
PY - 2009/12/1
Y1 - 2009/12/1
N2 - For patients with brain tumors identification of diagnostic and prognostic markers in easy accessible biological material, such as plasma or cerebrospinal fluid (CSF), would greatly facilitate patient management. MIC-1/GDF15 (growth differentiation factor 15) is a secreted protein of the TGF-beta superfamily and emerged as a candidate marker exhibiting increasing mRNA expression during malignant progression of glioma. Determination of MIC-1/GDF15 protein levels by ELISA in the CSF of a cohort of 94 patients with intracranial tumors including gliomas, meningioma and metastasis revealed significantly increased concentrations in glioblastoma patients (median, 229 pg/ml) when compared with control cohort of patients treated for non-neoplastic diseases (median below limit of detection of 156 pg/ml, p < 0.0001, Mann-Whitney test). However, plasma MIC-1/GDF15 levels were not elevated in the matching plasma samples from these patients. Most interestingly, patients with glioblastoma and increased CSF MIC-1/GDF15 had a shorter survival (p = 0.007, log-rank test). In conclusion, MIC-1/GDF15 protein measured in the CSF may have diagnostic and prognostic value in patients with intracranial tumors.
AB - For patients with brain tumors identification of diagnostic and prognostic markers in easy accessible biological material, such as plasma or cerebrospinal fluid (CSF), would greatly facilitate patient management. MIC-1/GDF15 (growth differentiation factor 15) is a secreted protein of the TGF-beta superfamily and emerged as a candidate marker exhibiting increasing mRNA expression during malignant progression of glioma. Determination of MIC-1/GDF15 protein levels by ELISA in the CSF of a cohort of 94 patients with intracranial tumors including gliomas, meningioma and metastasis revealed significantly increased concentrations in glioblastoma patients (median, 229 pg/ml) when compared with control cohort of patients treated for non-neoplastic diseases (median below limit of detection of 156 pg/ml, p < 0.0001, Mann-Whitney test). However, plasma MIC-1/GDF15 levels were not elevated in the matching plasma samples from these patients. Most interestingly, patients with glioblastoma and increased CSF MIC-1/GDF15 had a shorter survival (p = 0.007, log-rank test). In conclusion, MIC-1/GDF15 protein measured in the CSF may have diagnostic and prognostic value in patients with intracranial tumors.
KW - Cerebrospinal fluid
KW - Glioblastoma
KW - MIC-1/GDF15
KW - Prognostic biomarker
UR - http://www.scopus.com/inward/record.url?scp=70350712285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350712285&partnerID=8YFLogxK
U2 - 10.1002/ijc.24639
DO - 10.1002/ijc.24639
M3 - Article
C2 - 19521960
AN - SCOPUS:70350712285
SN - 0020-7136
VL - 125
SP - 2624
EP - 2630
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 11
ER -